CSL

Phone: 61 3 9389 1911

Fax: 61 3 9389 1434

Web: https://www.csl.com

Type	Public
Traded as	ASX: CSL S&P/ASX 200 component
Industry	Biotechnology
Founded	1916 (Federal government department), 1994 (privatised)
Headquarters	Parkville, Melbourne, Victoria, Australia (Global),
Key people	Paul Perreault (CEO)
Products	blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue	AUD$10.61 billion (2021)
Net income	USD$1.919 billion (2019)
Number of employees	30,000 person (2022)
Divisions	CSL Behring CSL Seqirus CSL Plasma CSL Vifor
Website	www.csl.com

Delivering on promises is what we do at CSL. Over a century ago in Melbourne, Victoria, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.

For detailed contact information visit location pages below.